The Partial Weight Transfer Walking Therapy Device developed and manufactured in Turkey within the BAMA technology is an innovative product in the VisioGait Medical Devices® segment. VisioGait®; SVO (cerebrovascular event) is a rehabilitation concept specially developed in rehabilitation, taking into account the loss of function that occurs in patients.
Everything you need to know about the features and benefits of the VisioGait Partial Weight Transfer Walking Therapy Device by BAMA Teknoloji need to know.
The product combines a comfortable and safe walking therapy environment with a visual infrastructure that makes the sensation process more focused and enjoyable. VisioGait® is equipped with sensors that continuously monitor the patient's joint positions and weight distribution. The information collected by the sensors is used in Visual Motivation System (GMS) software specifically designed for rehabilitation. This allows the patient to perform the tasks encouraged by the animation on the monitor placed in front of him with body movements.
MAMA was founded in 2010 and produces exoskeletons as well as other solutions such as active knee prostheses, public disinfection devices, intelligent drones and serious game design. BAMA Technology is an R&D company established in 2010 in Ankara to develop robotic rehabilitation systems. BAMA Technology is certified to ISO 13485:2003, which certifies compliance with international standards for medical device design, production and service. This legislation establishes the standards used in many countries around the world to protect the health and safety of patients. RoboGait and FreeGait products manufactured by Bama Technology have CE certificates attesting to compliance with European legislation on the protection of patient health and safety in medical devices.
By loading the video, you accept YouTube's privacy policy.
Learn more
Image sources: All images and graphics are copyrighted and property of ©.
2023
BAMA Teknoloji.
By loading the video, you accept YouTube's privacy policy.
Learn more